Interleukin 13– and Interleukin 17A–Induced Pulmonary Hypertension Phenotype Due to Inhalation of Antigen and Fine Particles from Air Pollution

Pulmonary hypertension has a marked detrimental effect on quality of life and life expectancy. In a mouse model of antigen-induced pulmonary arterial remodeling, we have recently shown that coexposure to urban ambient particulate matter (PM) significantly increased the thickening of the pulmonary arteries and also resulted in significantly increased right ventricular systolic pressures. Here we interrogate the mechanism and show that combined neutralization of interleukin 13 (IL-13) and IL-17A significantly ameliorated the increase in right ventricular systolic pressure, the circumferential muscularization of pulmonary arteries, and the molecular change in the right ventricle. Surprisingly, our data revealed a protective role of IL-17A for the antigen- and PM-induced severe thickening of pulmonary arteries. This protection was due to the inhibition of the effects of IL-13, which drove this response, and the expression of metalloelastase and resistin-like molecule α. However, the latter was redundant for the arterial thickening response. Anti-IL-13 exacerbated airway neutrophilia, which was due to a resulting excess effect of IL-17A, confirming concurrent cross inhibition of IL-13- and IL-17A-dependent responses in the lungs of animals exposed to antigen and PM. Our experiments also identified IL-13/IL-17A-independent molecular reprogramming in the lungs induced by exposure to antigen and PM, which indicates a risk for arterial remodeling and protection from arterial constriction. Our study points to IL-13- and IL-17A-coinduced inflammation as a new template for biomarkers and therapeutic targeting for the management of immune response–induced pulmonary hypertension.

[1]  Seung-Hyun Cho,et al.  Comparative Toxicity of Size-Fractionated Airborne Particulate Matter Obtained from Different Cities in the United States , 2007, Inhalation toxicology.

[2]  J. Clardy,et al.  A bacterial sulfonolipid triggers multicellular development in the closest living relatives of animals , 2012, eLife.

[3]  W. Seeger,et al.  Impact of TASK-1 in Human Pulmonary Artery Smooth Muscle Cells , 2006, Circulation research.

[4]  W. Chung,et al.  Polymorphism in the angiotensin II type 1 receptor (AGTR1) is associated with age at diagnosis in pulmonary arterial hypertension. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  W. Seeger,et al.  Inducible NOS Inhibition Reverses Tobacco-Smoke-Induced Emphysema and Pulmonary Hypertension in Mice , 2011, Cell.

[6]  Sung-Hyun Park,et al.  Modification of Hemodynamic and Immune Responses to Exposure with a Weak Antigen by the Expression of a Hypomorphic BMPR2 Gene , 2013, PloS one.

[7]  Jennifer R. Clark,et al.  Particulate Matter–Induced Airway Hyperresponsiveness Is Lymphocyte Dependent , 2010, Environmental health perspectives.

[8]  M. Humbert,et al.  Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. , 1995, American journal of respiratory and critical care medicine.

[9]  Monica Kraft,et al.  IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. , 2012, The Journal of allergy and clinical immunology.

[10]  S. Pendergrass,et al.  Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. , 2011, Arthritis and rheumatism.

[11]  W. Seeger,et al.  Human RELMβ is a mitogenic factor in lung cells and induced in hypoxia , 2006, FEBS letters.

[12]  N. King,et al.  Cell differentiation and morphogenesis in the colony-forming choanoflagellate Salpingoeca rosetta. , 2011, Developmental biology.

[13]  B. Dahal,et al.  Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[14]  Antonio Abbate,et al.  Mechanisms of right heart failure—A work in progress and a plea for failure prevention , 2013, Pulmonary circulation.

[15]  F. Finkelman,et al.  Resistin-like molecule-α regulates IL-13-induced chemokine production but not allergen-induced airway responses. , 2012, American journal of respiratory cell and molecular biology.

[16]  G. Butrous,et al.  Pulmonary vascular disease associated with parasitic infection--the role of schistosomiasis. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[17]  H. Ghofrani,et al.  Updated evidence-based treatment algorithm in pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[18]  R. Johns,et al.  FIZZ1/RELM&agr;, a Novel Hypoxia-Induced Mitogenic Factor in Lung With Vasoconstrictive and Angiogenic Properties , 2003, Circulation research.

[19]  C. Uyttenhove,et al.  Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis , 2009, The Journal of experimental medicine.

[20]  Gregory E Crawford,et al.  Epigenetic instability of cytokine and transcription factor gene loci underlies plasticity of the T helper 17 cell lineage. , 2010, Immunity.

[21]  G. Butrous,et al.  Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective. , 2010, Chest.

[22]  J. Loscalzo,et al.  Pulmonary arterial hypertension. , 2004, Annals of medicine.

[23]  M. Humbert,et al.  Systemic sclerosis-associated pulmonary arterial hypertension. , 2010, American journal of respiratory and critical care medicine.

[24]  M. Selman,et al.  S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis. , 2013, American journal of respiratory and critical care medicine.

[25]  R. Lafyatis,et al.  The Pronounced Th17 Profile in Systemic Sclerosis (SSc) Together with Intracellular Expression of TGFβ and IFNγ Distinguishes SSc Phenotypes , 2009, PloS one.

[26]  R. de Waal Malefyt,et al.  Interleukin-19: A Constituent of the Regulome That Controls Antigen Presenting Cells in the Lungs and Airway Responses to Microbial Products , 2011, PloS one.

[27]  S. Wenzel,et al.  Dupilumab in persistent asthma with elevated eosinophil levels. , 2013, The New England journal of medicine.

[28]  V. Kurup,et al.  IL-13 Regulates the Immune Response to Inhaled Antigens1 , 2005, The Journal of Immunology.

[29]  J. Chabon,et al.  Protective role of IL-6 in vascular remodeling in Schistosoma pulmonary hypertension. , 2013, American journal of respiratory cell and molecular biology.

[30]  Sung-Hyun Park,et al.  Right ventricular systolic pressure measurements in combination with harvest of lung and immune tissue samples in mice. , 2013, Journal of visualized experiments : JoVE.

[31]  L. Farkas,et al.  Blocking Macrophage Leukotriene B4 Prevents Endothelial Injury and Reverses Pulmonary Hypertension , 2013, Science Translational Medicine.

[32]  R. Barst,et al.  Survival with first-line bosentan in patients with primary pulmonary hypertension , 2005, European Respiratory Journal.

[33]  Lee， Jk,et al.  Lebrikizumab treatment in adults with asthma. , 2011 .

[34]  M. Wills-Karp,et al.  Complement factor 3 mediates particulate matter-induced airway hyperresponsiveness. , 2002, American journal of respiratory cell and molecular biology.

[35]  C. Long,et al.  Chronic Pulmonary Artery Pressure Elevation Is Insufficient to Explain Right Heart Failure , 2009, Circulation.

[36]  C. Long,et al.  Regulatory T Cells Limit Vascular Endothelial Injury and Prevent Pulmonary Hypertension , 2011, Circulation research.

[37]  Dan R. Littman,et al.  Th17 and Regulatory T Cells in Mediating and Restraining Inflammation , 2010, Cell.

[38]  Aleksandar Milosavljevic,et al.  Proinflammatory Role for let-7 MicroRNAS in Experimental Asthma* , 2010, The Journal of Biological Chemistry.

[39]  J. Pober,et al.  Interleukin-17 and Interferon-γ Are Produced Concomitantly by Human Coronary Artery–Infiltrating T Cells and Act Synergistically on Vascular Smooth Muscle Cells , 2009, Circulation.

[40]  Y. Fukuchi,et al.  Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[41]  Won-Kyung Cho,et al.  IL-13-induces Vascular Remodeling And Pulmonary Arterial Hyptertension Via Arginase 2-dependent Pathway , 2010, ATS 2010.

[42]  R. Johns,et al.  Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMalpha) induces the vascular and hemodynamic changes of pulmonary hypertension. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[43]  D. Patel,et al.  Effect of IL-17A blockade with secukinumab in autoimmune diseases , 2012, Annals of the rheumatic diseases.

[44]  G. Butrous,et al.  Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling. , 2010, The American journal of pathology.

[45]  M. Wills-Karp,et al.  Ambient urban Baltimore particulate-induced airway hyperresponsiveness and inflammation in mice. , 2001, American journal of respiratory and critical care medicine.

[46]  M. Fujita,et al.  Pulmonary hypertension in TNF-alpha-overexpressing mice is associated with decreased VEGF gene expression. , 2002, Journal of applied physiology.

[47]  D. Corry,et al.  Interleukin 13 and the evolution of asthma therapy. , 2012, American journal of clinical and experimental immunology.

[48]  N. Esmaeil,et al.  Perspective: Ambient Air Pollution: Inflammatory Response and Effects on the Lung's Vasculature , 2014, Pulmonary circulation.

[49]  E. White,et al.  Interleukin-17 Drives Pulmonary Eosinophilia following Repeated Exposure to Aspergillus fumigatus Conidia , 2012, Infection and Immunity.

[50]  F. Martinez,et al.  Pulmonary hypertension in chronic lung diseases. , 2013, Journal of the American College of Cardiology.

[51]  P. Hirth,et al.  Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  D. Littman,et al.  Plasticity of CD4+ T cell lineage differentiation. , 2009, Immunity.

[53]  Chris Cheadle,et al.  Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMα) in chronic hypoxia- and antigen-mediated pulmonary vascular remodeling , 2013, Respiratory Research.

[54]  H. Olschewski,et al.  Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. , 2013, Chest.

[55]  A. Olschewski,et al.  Origin of neomuscularized vessels in mice exposed to chronic hypoxia , 2011, Respiratory Physiology & Neurobiology.

[56]  W. Seeger,et al.  Increased neutrophil mediator release in patients with pulmonary hypertension – suppression by inhaled iloprost , 2003, Thrombosis and Haemostasis.

[57]  C. Cheadle,et al.  Hypoxia-Induced Mitogenic Factor (HIMF/FIZZ1/RELMα) Increases Lung Inflammation and Activates Pulmonary Microvascular Endothelial Cells via an IL-4–Dependent Mechanism , 2010, The Journal of Immunology.

[58]  R. Trembath,et al.  Primary Pulmonary Hypertension Is Associated With Reduced Pulmonary Vascular Expression of Type II Bone Morphogenetic Protein Receptor , 2002, Circulation.

[59]  M. Humbert,et al.  Inflammation in pulmonary arterial hypertension , 2003, European Respiratory Journal.

[60]  N. Morrell,et al.  BMP type II receptor deficiency confers resistance to growth inhibition by TGF-β in pulmonary artery smooth muscle cells: role of proinflammatory cytokines. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[61]  E. Bettelli,et al.  Cutting Edge: The Pathogenicity of IFN-γ–Producing Th17 Cells Is Independent of T-bet , 2013, The Journal of Immunology.

[62]  W. Seeger,et al.  Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.

[63]  W. Seeger,et al.  Dysregulated Bone Morphogenetic Protein Signaling in Monocrotaline-Induced Pulmonary Arterial Hypertension , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[64]  Subhashis Banerjee,et al.  Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. , 2012, The New England journal of medicine.

[65]  D. Bernstein,et al.  FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. , 2013, The Journal of clinical investigation.

[66]  T. L. Le Cras,et al.  Chronic Allergic Inflammation Causes Vascular Remodeling and Pulmonary Hypertension in Bmpr2 Hypomorph and Wild-Type Mice , 2012, PloS one.

[67]  W. Seeger,et al.  Dysregulation of the IL-13 receptor system: a novel pathomechanism in pulmonary arterial hypertension. , 2010, American journal of respiratory and critical care medicine.

[68]  J. Renauld,et al.  IL-17A–Producing γδ T and Th17 Lymphocytes Mediate Lung Inflammation but Not Fibrosis in Experimental Silicosis , 2010, The Journal of Immunology.

[69]  H. Olschewski,et al.  A novel channelopathy in pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[70]  Su-xia Wang,et al.  Involvement of TLR2 and TLR4 and Th1/Th2 shift in inflammatory responses induced by fine ambient particulate matter in mice , 2012, Inhalation toxicology.

[71]  M. Rabinovitch.  Molecular pathogenesis of pulmonary arterial hypertension. , 2008, The Journal of clinical investigation.

[72]  G. Scano,et al.  Cardiopulmonary adaptation to exercise in coal miners. , 1980, Archives of environmental health.

[73]  M. Rothenberg,et al.  Resistin-like molecule alpha enhances myeloid cell activation and promotes colitis. , 2008, The Journal of allergy and clinical immunology.

[74]  R. Johns,et al.  Resistin-like molecule-beta in scleroderma-associated pulmonary hypertension. , 2009, American journal of respiratory cell and molecular biology.